Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Oxygen-Carbon Nanotubes as a Chemotherapy Sensitizer for Paclitaxel in Breast Cancer Treatment

  • Yongkun Wang,

    Affiliation Department of General Surgery, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

  • Chuanying Wang,

    Affiliation School of Mechanical and Power Engineering, Shanghai Jiaotong University, Shanghai, China

  • Yijun Jia,

    Affiliation Department of General Surgery, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

  • Xianhua Cheng,

    Affiliation School of Mechanical and Power Engineering, Shanghai Jiaotong University, Shanghai, China

  • Qing Lin,

    Affiliation Department of Oncology, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

  • Mingjie Zhu,

    Affiliation Department of Pathology, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

  • Yunshu Lu,

    Affiliation Department of General Surgery, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

  • Longlong Ding,

    Affiliation Department of General Surgery, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

  • Ziyi Weng ,

    wzysn88@163.com (ZW); kejinwu@163.com (KW)

    Affiliation Department of Anorectal Surgery, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

  • Kejin Wu

    wzysn88@163.com (ZW); kejinwu@163.com (KW)

    Affiliation Department of General Surgery, XinHua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Oxygen-Carbon Nanotubes as a Chemotherapy Sensitizer for Paclitaxel in Breast Cancer Treatment

  • Yongkun Wang, 
  • Chuanying Wang, 
  • Yijun Jia, 
  • Xianhua Cheng, 
  • Qing Lin, 
  • Mingjie Zhu, 
  • Yunshu Lu, 
  • Longlong Ding, 
  • Ziyi Weng, 
  • Kejin Wu
PLOS
x

Abstract

Objective

To study the in vivo and in vitro effects of adding oxygen carbon nanotubes (CNTs) to chemotherapy for breast cancer.

Methods

MCF-7 and SK-BR-3 breast cancer cells were co-cultured with paclitaxel and then exposed to oxygen-CNTs under hypoxic conditions. Cell proliferation, viability, and apoptosis rate were analyzed. Hypoxia-inducible factor-1 alpha (HIF-1α) expression was measured using reverse transcription-polymerase chain reaction (RT-PCR) and western blot. Nude mice were used as a human breast cancer model to explore the impact of oxygen-CNTs on the in vivo chemotherapeutic effect of paclitaxel.

Results

Oxygen-CNTs had no significant effects on the growth of breast cancer cells under normoxia and hypoxia. However, in the hypoxic environment, oxygen-CNTs significantly enhanced the inhibitory effect of paclitaxel on cell proliferation, as well as the apoptosis rate. Under hypoxia, downregulation of HIF-1α and upregulation of caspase-3, caspase-8, caspase-9, LC3 and Beclin-1 were observed when paclitaxel was combined with oxygen-CNT. Furthermore, addition of oxygen-CNTs to chemotherapy was found to significantly reduce tumor weight in the tumor-bearing mice model.

Conclusions

Oxygen-CNTs can significantly increase the chemotherapeutic effect of paclitaxel on breast cancer cells. Oxygen-CNTs may be a potential chemosensitizer in breast cancer therapy.

Introduction

Breast cancer is one of the most common cancers in women, affecting 1.2 million women in the world and being responsible for the death of 500,000 women each year. China is among the countries with the fastest growing incidence of breast cancer, and statistical data from the Chinese Anti-Cancer Association show that in recent years, the incidence of breast cancer has been increasing by 3% every year, and has been accompanied by a decrease in the age of onset [1].

Despite great advances in breast cancer treatment, there are still cases of tumor resistance to treatments. Hypoxia is an important factor that affects the efficacy of treatment. Indeed, hypoxia significantly increases tumor resistance to chemotherapy and radiotherapy, and may also increase the invasiveness of the tumor [2], [3]. Hypoxia-inducible factor 1 alpha (HIF-1α) plays a key role in the effects of hypoxia in cancer cells. Indeed, HIF-1α expression is associated with survival of breast cancer patients after surgery [4]. Therefore, overcoming the effects of hypoxia might improve the efficacy of breast cancer treatments.

In recent years, nanotechnology has been used for a wide range of applications in medicine and biology. Carbon nanotubes (CNTs) are expected to achieve a breakthrough in the treatment of breast cancer and other tumors by reducing the tumors' resistance to radiotherapy and chemotherapy [5][7]. Functional CNTs have a potential for protein and gene transfer across the cell membrane and into the nucleus [8][17]. The present study is based on CNTs' characteristics that were developed using a mixed acid purification method. CNTs' surface is rich in hydroxyl and carboxyl functional groups, which increases the oxygen-binding capacity of these CNTs, making them efficient oxygen carriers.

We undertook the present study to test the hypothesis that oxygen-CNTs inhibit breast cancer cell proliferation induced by HIF1α. Our findings show that oxygen-CNTs are potent chemosensitizers that improve the effects of paclitaxel in vivo and in vitro. Our results further indicate that oxygen-CNTs induce this effect by improving the hypoxia status and sensitivity to chemotherapy.

Materials and Methods

Materials

Functional oxygen single-walled carbon nanotubes (SWCNTs) were provided by the Mechanical and Power Engineering College of Shanghai Jiaotong University (Shanghai, China). DMEM, RPMI 1640 medium, fetal bovine serum (FBS), penicillin and streptomycin were from GIBCO (Invitrogen Inc., Carlsbad, CA, USA).

Ethical considerations

Nude mice were used as an animal model to study the biological effects of oxygen-CNTs. This study was carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Xinhua Hospital, affiliated to Shanghai Jiaotong University School of Medicine, China. Surgeries were performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.

CNT pretreatment, hydroxylation and X-ray photoelectron spectroscopy analysis

CNTs were purified by acid treatment and high energy ball mill; they were of >95% purity, 0.5–2 µm in length, and 10–20 nm in diameter. Single-wall carbon nanotubes (1 g) (XFNANO Materials Tech. Co., Ltd., Nanjing, China) were ground in an agate mortar for 1 h. Then, 0.1 g of the ground CNT powder was placed in a 500-mL Erlenmeyer containing 50 mL of an acid mixture (3∶1 v/v ratio of 98% sulfuric acid and 78% nitric acid), for a concentration of 2 mg of nanotubes per 1 ml of acid solution. The solution was treated in an oscillating ultrasonic bath (SKYMEN Cleaning Equipment Co., Ltd., Shenzhen, China) for 2 h at room temperature. Oxidative reflux was conducted for 0.5 h at 100°C, and then the reaction liquid were naturally cooled to room temperature, after which 300 mL of deionized water was added. The flask was kept still for some time until the precipitate containing oxygen-CNTs had deposited at the bottom of the flask. The supernatant was discarded, and the turbid liquid that remained was filtered through a millipore filter. The filter paper containing the oxygen-CNT residue was placed in a beaker containing deionized water, and was ultrasonicated (SKYMEN Cleaning Equipment Co., Ltd., Shenzhen, China) to separate the CNTs. The solution was poured into an Erlenmeyer and repeatedly washed, filtered and resuspended until the pH value was neutral. The oxygen-CNT-containing solution was then dried in an oven at 60°C. We obtained a black powder that was used for the further experiments.

Nanotubes analysis

The constituent elements (oxygen, carbon and nitrogen) of the oxygen CNTs were detected by X-ray photoelectron spectroscopy (XPS) analysis.

Carbon nanotubes were dispersed, dropped on a copper screen and observed under a JEM-2010 high-resolution transmission electron microscope (TEM) to assess their distribution in solution.

Cell culture

The breast cancer cell lines MCF-7 and SK-BR-3 were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in DMEM and RPMI1640 complete media (containing 10% FBS, 100 U/L of penicillin, and 100 U/L of streptomycin). The cultures were incubated in a normoxic incubator (37°C, 5% CO2) for 12h and then in a hypoxic incubator (37°C, 5% CO2, 1% O2, 94% N2) for 48 h. Adherent cells were picked up from the culture and subjected to 0.25% trypsin digestion. Cells in the logarithmic growth phase were used for subsequent experiments.

Cell proliferation

The water-soluble tetrazolium salt assay (WST-1; Nanjing KeyGen Biotech Co., Nanjing, China) was used to determine cell viability. To conduct the assay, 10 µL of WST-1 (5 mg/mL) working solution was added to each well at a final concentration of 500 µg/mL. After the mixture in each well was incubated for 2.5 h, the absorbance was read with a microplate reader (uQuant; Bio-Tek Services Inc., Richmond, VA, USA) at 450 nm. Relative cell viability was expressed as the percentage of viable cells divided by the number of viable cells in the control wells that were not treated with functional CNTs. The inhibition rate was calculated using the formula: cell inhibition rate = [1−absorbance of the experimental group/control group absorbance]×100%.

Cell apoptosis

Cells in the logarithmic growth phase were seeded in 6-well plates at a density of 105/mL and incubated at 37°C in an atmosphere containing 5% CO2, 1% O2, and 94% N2, for 24 h. The cells were then harvested by trypsinization and washed once with phosphate-buffered saline (PBS, pH 7.4). After centrifugation, the cells were resuspended in 100 µL of binding buffer, and then stained with FITC-Annexin V and propidium iodide (Invitrogen Inc., Carlsbad, CA, USA) for analysis of cell apoptosis. The reaction was developed under dark conditions for 10 min, after which 400 µL of binding buffer was added to the wells. Cells were counted using a flow cytometer (Model BD LSR II; BD Bioscience, San Jose, CA, USA) (channel selection FL1 and FL2).

Survivin and Ki67 mRNA levels by semi-quantitative RT-PCR

After treatment with paclitaxel and oxygen-CNTs for 48 h, cells were harvested. Total RNA was extracted using Trizol (Takara Bio, Otsu, Japan), and cDNA was produced by reverse transcription and amplification using the reverse transcription-polymerase chain reaction kit (RT-PCR, Takara Bio, Otsu, Japan). The primers were synthesized by Sangon Co. (Shanghai, China). The primers for GADPH were 5′-ACC ACA GTC CAT GCC ATC AC-3′ (sense) and 5′-CCA CCA CCC TGT TGC TGT A-3′ (antisense) (471 bp). The primers for Ki67 were 5′-ATC GTC CCA GGT GGA AGA GTT-3′ (sense) and 5′-ATA GTA ACC AGG CGT CTC GTG G-3′ (antisense) (126 bp). The primers for survivin were 5′-AGC CCT TTC TCA AGG ACC AC-3′ (sense) and 5′-GCA CTT TCT TCG CAG TTT CC-3′ (antisense) (363 bp). PCR conditions were: 30 cycles at 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s. The products were detected using 1.5–2% agarose gel (Invitrogen Inc., Carlsbad, CA, USA) electrophoresis. Results were analyzed using the Bio-rad Gel DocTM XR+ imaging system (Bio-Rad Laboratories Inc., Hercules, CA, USA).

Caspase, LC3 and Beclin-1 protein expression by western blot

Cells were washed and then suspended in 100 µL of lysate (sodium dodecyl sulfate+phenylmethyl sulfonylfluoride, SDS+PMSF). The total protein concentration was determined using the bicinchoninic acid (BCA) assay and a microplate reader at 562 nm. After an equal amount of protein was loaded in each lane, the proteins were separated using 10% SDS w/v polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto a polyvinylidene difluoride (PVDF) membrane. After blocking the membrane with 5% (w/v) skim milk, target proteins were immunodetected using specific antibodies. All primary antibodies were used in a 1∶1000 dilution and incubated overnight at 4°C. After washing with Tris-buffered saline with Ttween-20 (TBST) three times for 20 min each, horseradish peroxidase (HRP)-conjugated antibody (Wuhan Boster Biological Engineering Co., Wuhan, China) was added as the secondary antibody. Positive bands were detected using ECL Plus Western Blotting Detection Regents. The results were scanned using the Bio-Rad Chemi Doc™ XRS+imaging system (Bio-Rad Laboratories Inc., Hercules, CA, USA). Caspase-3, caspase-8, and caspase-9 mouse monoclonal antibodies and p27 rabbit monoclonal antibodies were purchased from Santa Cruz (Santa Cruz, CA, USA). β-Actin, LC3, and Beclin-1 rabbit monoclonal antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA).

Chemotherapeutic effect of oxygen-CNTs in tumor-bearing animal models

Six-week-old female Balb/c nu/nu mice were obtained from the Shanghai Animal Center (Shanghai, China). The animals were housed in sterilized cages with filtered air, 12-h light-dark cycle, and had free access to sterile water and food. After 1 week of acclimatization, breast cancer cells were injected into the right flanks of each mouse (5×106 cells, twice a week). After the tumors were allowed to develop for 2 weeks, the animals were randomly grouped into one of three groups (n = 6/group). The animals in the vehicle group were administered an intraperitoneal injection of 0.9% normal saline. The animals in the paclitaxel group were intraperitoneally administered 20 µg/kg body weight paclitaxel each week. Finally, the animals in the oxygen-CNT group were intraperitoneally administered 5 mg/kg body weight oxygen-CNTs each week local injection with lots of dot around the tumor. At the end of the experiment, the animals were euthanized with a CO2 overdose and decapitated. Tumor tissue from each animal was excised and then weighed after the excess normal tissue was trimmed off. The inhibition rate was calculated using the formula inhibition rate = [(Weightcontrol group−Weight experimental group)/Weightcontrol group]×100%.

Statistical analysis

For the in vitro cell culture study, each experiment was repeated at least three times. Data are presented as mean ± standard deviation from multiple independent experiments. For the in vivo animal study, we obtained similar results from two independent experiments, and only one representative data set was used. Statistical significance was analyzed using one-way ANOVA and Dunnett's test. All analyses were performed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA). A P-value<0.05 was considered statistically significant.

Results

Physical and chemical characteristics of oxygen-CNTs

Figure 1 indicates oxygen inclusion, with the oxygen absorption peak being between 600 eV and 500 eV, and the carbon absorption peak around 300 eV. These findings indicate that the CNTs contained oxygen (Fig. 1). The oxygen-CNTs contained 14.04% of oxygen, 82.68% of carbon, and 3.28% of nitrogen.

thumbnail
Figure 1. Physical and chemical characteristics of oxygen-CNTs.

A. Analysis of the hydroxylation of carbon nanotubes by XPS. B. Data smoothing of the hydroxylation results. C. Transmission electronic microscopy image showing that the oxygen-CNTs well dispersed in solution.

https://doi.org/10.1371/journal.pone.0104209.g001

TEM pictures of functional oxygen single-walled carbon nanotubes after oxygen modification showed that the carbon nanotubes were evenly dispersed in solution (Fig. 1).

Effect of oxygen-CNTs on the effects of paclitaxel

The WST-1 assay showed that the oxygen-CNTs had no influence on the activity of MCF-7 cells in the normoxic environment (OD <0.2) (Fig. 2A). Moreover, under both normoxic and hypoxic conditions, the CNTs did not have a significant impact on cell proliferation and activity in both breast cancer cell lines. Gradient concentrations (25, 50, 75 and 100 µg/mL) of oxygen-CNTs with paclitaxel treatment showed increasing inhibition effects (Fig. 2B) on breast cancer cells compared with the control group. Cell activity of the paclitaxel group was reduced by 20% at 48 h, although the oxygen-CNTs+paclitaxel group showed a further decrease of 10–25%. Thus, these results demonstrate that oxygen-CNTs could improve the inhibitory effect of paclitaxel on cell proliferation.

thumbnail
Figure 2. Effect of oxygen-CNTs on the inhibitory effect of paclitaxel.

A. Effect of oxygen-CNTs on breast cancer cell activity under normoxic and hypoxic conditions. B. Impact of oxygen-CNTs combined with paclitaxel on cell activity under hypoxia.

https://doi.org/10.1371/journal.pone.0104209.g002

The cell apoptosis rates determined using flow cytometry are shown in Figure 3. The apoptosis rate in the paclitaxel treatment group was 15% higher than that in the control group, and the apoptosis rate in the oxygen-CNT+paclitaxel group was 20% higher than that in the paclitaxel group (all P<0.05, Table 1), which indicated that oxygen-CNTs could enhance the effects of paclitaxel on the cell apoptosis rate in both cell lines.

thumbnail
Figure 3. Effect of oxygen-CNTs and paclitaxel on cell apoptosis under hypoxia.

A: hypoxia group; B: paclitaxel group; C: oxygen-CNT group.

https://doi.org/10.1371/journal.pone.0104209.g003

thumbnail
Table 1. Effect of oxygen-CNTs and paclitaxel on cell apoptosis under hypoxia.

https://doi.org/10.1371/journal.pone.0104209.t001

HIF-1α, survivin and Ki67 mRNA expression

RT-PCR showed that survivin and Ki67 mRNA expression were significantly reduced by 30–45% with the addition of oxygen-CNTs compared with paclitaxel only (P<0.05, Fig. 4). Under hypoxia, there was an apparent increase in HIF-1α mRNA expression compared with normal conditions, and the addition of oxygen-CNTs led to a reduction in HIF-1α expression (Fig. 4).

thumbnail
Figure 4. Effect of oxygen-CNTs and paclitaxel on survivin, Ki67 and HIF-1α mRNA expression.

A. Oxygen-CNTs and affect survivin and Ki67 mRNA expression under hypoxic conditions. Typical figure (left) and analysis (right). 1: hypoxia group; 2: paclitaxel group; 3: oxygen-CNTs group. B. Effect of oxygen-CNTs on HIF-1α mRNA expression under normal and hypoxic conditions. Typical figure (left) and analysis (right). 1: normoxia group; 2: hypoxia group; 3: paclitaxel group; 4: oxygen-CNTs group.

https://doi.org/10.1371/journal.pone.0104209.g004

Caspase, LC3 and Beclin-1 protein expression

The expression of the apoptosis-related proteins caspase-3, caspase-8 and caspase-9, and of the autophagy-associated proteins LC3 and Beclin-1 was increased after 48 h of treatment, and the expression of these proteins further increased with the addition of oxygen-CNTs (all P<0.05, Fig. 5), indicating that CNTs significantly enhanced the apoptosis and autophagy effects of paclitaxel.

thumbnail
Figure 5. Effect of oxygen-CNTs and paclitaxel on the protein expression of HIF1α, caspase-3, caspase-8, caspase-9, LC3, and Beclin-1 under hypoxia.

Typical figure (left) and analysis (right).

https://doi.org/10.1371/journal.pone.0104209.g005

Tumor weight estimation

No significant difference was observed in body weight between the experimental and vehicle groups. In the control group, tumor weight was modest, and partial rupture of the tumor capsule led to death in one case. Moreover, the oxygen-CNT+paclitaxel group showed a greater decline of 20–25% in tumor weight and volume compared with the paclitaxel group. Both experimental groups showed an obvious decline in tumor weight compared with the control group, and there was no ulceration or death in the experimental groups (P<0.05) (Table 2).

thumbnail
Table 2. Effect of oxygen-CNTs on chemotherapy in animal models of breast cancer.

https://doi.org/10.1371/journal.pone.0104209.t002

Discussion

The aim of the present study was to assess the in vivo and in vitro effects of adding oxygen-CNTs to chemotherapy for hypoxic breast cancer. Results showed that in the normoxic and hypoxic environments, oxygen-CNTs had no significant effects on the growth of breast cancer cells. However, under hypoxia, oxygen-CNTs significantly enhanced the inhibitory effect of paclitaxel on cell proliferation, as well as the apoptosis rate. Under hypoxia, downregulation of HIF-1α and upregulation of caspase-3, caspase-8, caspase-9, LC3 and Beclin-1 were observed when paclitaxel was combined with oxygen-CNT. Furthermore, addition of oxygen-CNTs to chemotherapy was found to significantly reduce tumor weight in the tumor-bearing mice model.

CNTs present a high surface area, excellent chemical stability and are able to adsorb and conjugate with many chemical elements or macromolecules. Furthermore, they are able to enter into cells and to keep the bound molecules intact during transport [18], [19]. Therefore, CNTs are ideal agents for treatment delivery to tumor cells, and their first use was the delivery of chemotherapy directly into tumor cells [20][22]. In addition to drug delivery, CNTs have been used for antitumor immunotherapy, local antitumor hyperthermia therapy, for DNA delivery and for reactive oxygen species scavenging [23]. Furthermore, since CNTs do not rely upon active transport systems and are not subjected to multidrug resistance (MDR) mechanisms, they can be used to overcome MDR [24]. However, even if greatly promising, this approach does not overcome an important problem encountered in solid cancers: hypoxia.

Since tumors grow rapidly, the proliferation rate of tumor cells is higher than that of cells in the surrounding blood vessels, leading to severe local tissue hypoxia, which triggers the tumor cells into a series of stress responses [25], [26]. These responses lead to an increased resistance of cells to radiations and to chemotherapy [27], including paclitaxel [28], and leading to worst prognosis [29]. Therefore, delivering oxygen directly to the cells within solid tumors might be a way of overcoming hypoxia and hypoxia-induced resistance.

HIF-1 plays a key regulatory role in angiogenesis; it is associated with tumor development, invasion and metastasis, and affects the prognosis of most malignant tumors [30], [31]. The overexpression of HIF-1α has been detected in certain cancers such as gastric, breast and lung cancer [3], [32]. Moreover, the target genes of HIF-1α are involved in anaerobic glucose metabolism, oxygen transport, angiogenesis and vascular dilatation [32], which are key processes in tumorigenesis and malignant progression. It has also been reported that the expression of HIF-1α in most tumor tissues was related to tumor invasion, metastasis and prognosis [33]. HIF-1α is involved in the hypoxia-induced resistance to paclitaxel [34].

In the present study, under both normoxic and hypoxic conditions, oxygen-CNTs alone did not have an effect on the growth of breast cancer cells. However, oxygen-CNTs combined with paclitaxel showed more pronounced inhibition of the activity of breast cancer cells than paclitaxel alone under hypoxic conditions. These results are in agreement with previous studies that showed that the reoxygenation of hypoxic cancer cells led to better responses to paclitaxel treatment [35], [36]. Furthermore, oxygen-CNT treatment led to decreased HIF-1α levels, suggesting that delivery of oxygen to the cells decreased the expression of HIF-1α, decreasing the resistance to paclitaxel [34]. This resulted in the increase in proteins involved in apoptosis (caspase-3, caspase-8 and caspase-9) and autophagy (LC3 and Beclin-1), which are, at least in part, under HIF-1α control [37][39], as well as proteins that are involved in cell survival and growth (survivin and Ki67) [40], [41]. This resulted in a better in vivo tumor response to oxygen-CNTs and paclitaxel in the mice model. In addition, animals did not suffer from toxicity from the CNTs, as previously shown [42].

Therefore, it is possible that the addition of oxygen-CNTs under hypoxic conditions increased the availability of oxygen to the cells, increasing their sensitivity to paclitaxel and subsequently increasing apoptosis and autophagy. However, the specific mechanism by which oxygen-CNTs improve the chemotherapeutic effect of anti-cancer drugs needs to be further studied. The addition of oxygen to the cells did not seem to be toxic by itself. Therefore, we assume that the effects we observed were due to the chemo-sensitizing effects via decreased HIF-1α expression.

Conclusions

Oxygen-CNTs improved the hypoxia status of breast cancer cells in vitro and in vivo, and significantly improved the chemotherapeutic effect of paclitaxel. Oxygen-CNTs may therefore be a potential chemotherapy sensitizer for breast cancer treatment.

Acknowledgments

The authors gratefully acknowledge the assistance of Prof. Yingbin Liu (Laboratory of General Surgery and Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine; Research Institute of Biliary Tract Disease, Affiliated to Shanghai Jiao Tong University School of Medicine, China) and Dr. Lishun Wang (Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education).

Author Contributions

Conceived and designed the experiments: YW ZW KW. Performed the experiments: YW CW XC MZ YL. Analyzed the data: YW CW YJ QL YL. Contributed reagents/materials/analysis tools: QL MZ YL LD ZW KW. Wrote the paper: YW CW YJ XC QL. Applied for funding: YW ZW KW.

References

  1. 1. Shao ZM (2011) Basic points of interpretation of the Chinese Anti-Cancer Association of breast cancer treatment guidelines and norms. Chin J Practical Surg 10: 915–917.
  2. 2. Wang YK, Wu KJ, Lin Q (2011) Research progress radiosensitivity and hypoxia. J Surg Concepts Pract 16: 94–96.
  3. 3. Korkeila EA, Sundstrom J, Pyrhonen S, Syrjanen K (2011) Carbonic anhydrase IX, hypoxia-inducible factor-1alpha, ezrin and glucose transporter-1 as predictors of disease outcome in rectal cancer: multivariate Cox survival models following data reduction by principal component analysis of the clinicopathological predictors. Anticancer research 31: 4529–4535.
  4. 4. Witters L, Engle L, Lipton A (2002) Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncology reports 9: 1163–1166.
  5. 5. Prylutska S, Bilyy R, Shkandina T, Rotko D, Bychko A, et al. (2013) Comparative study of membranotropic action of single- and multi-walled carbon nanotubes. Journal of bioscience and bioengineering 115: 674–679.
  6. 6. Shao W, Paul A, Zhao B, Lee C, Rodes L, et al. (2013) Carbon nanotube lipid drug approach for targeted delivery of a chemotherapy drug in a human breast cancer xenograft animal model. Biomaterials 34: 10109–10119.
  7. 7. Neves LF, Krais JJ, Van Rite BD, Ramesh R, Resasco DE, et al. (2013) Targeting single-walled carbon nanotubes for the treatment of breast cancer using photothermal therapy. Nanotechnology 24: 375104.
  8. 8. Bonard JM, Dean KA, Coll BF, Klinke C (2002) Field emission of individual carbon nanotubes in the scanning electron microscope. Physical review letters 89: 197602.
  9. 9. Avouris P (2002) Carbon nanotubes electronics. Chemical Physics 281: 429–445.
  10. 10. Iijima S (1991) Helical microtubules of graphitic carbon. Nature 354: 56–58.
  11. 11. Bachtold A, Fuhrer MS, Plyasunov S, Forero M, Anderson EH, et al. (2000) Scanned probe microscopy of electronic transport in carbon nanotubes. Physical review letters 84: 6082–6085.
  12. 12. McEuen PL, Fuhrer MS, Park H (2002) Single-walled carbon nanotube electronics. Nanotechnology, IEEE Transactions 1: 78–85.
  13. 13. Durkop T, Getty S, Cobas E, Fuhrer MS (2004) Extraordinary mobility in semiconducting carbon nanotubes. Nano letters 4: 35–39.
  14. 14. Bachilo SM, Strano MS, Kittrell C, Hauge RH, Smalley RE, et al. (2002) Structure-assigned optical spectra of single-walled carbon nanotubes. Science 298: 2361–2366.
  15. 15. Zhang Z, Yang X, Zhang Y, Zeng B, Wang S, et al. (2006) Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clinical cancer research : an official journal of the American Association for Cancer Research 12: 4933–4939.
  16. 16. Kam NW, O'Connell M, Wisdom JA, Dai H (2005) Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proceedings of the National Academy of Sciences of the United States of America 102: 11600–11605.
  17. 17. Baughman RH, Zakhidov AA, de Heer WA (2002) Carbon nanotubes–the route toward applications. Science 297: 787–792.
  18. 18. Kumar R, Dhanawat M, Kumar S, Singh BN, Pandit JK, et al.. (2014) Carbon Nanotubes: A Potential Concept for Drug Delivery Applications. Recent patents on drug delivery & formulation:
  19. 19. Zhang Y, Bai Y, Yan B (2010) Functionalized carbon nanotubes for potential medicinal applications. Drug discovery today 15: 428–435.
  20. 20. Zhang W, Zhang Z, Zhang Y (2011) The application of carbon nanotubes in target drug delivery systems for cancer therapies. Nanoscale research letters 6: 555.
  21. 21. Madani SY, Naderi N, Dissanayake O, Tan A, Seifalian AM (2011) A new era of cancer treatment: carbon nanotubes as drug delivery tools. International journal of nanomedicine 6: 2963–2979.
  22. 22. Lay CL, Liu J, Liu Y (2011) Functionalized carbon nanotubes for anticancer drug delivery. Expert review of medical devices 8: 561–566.
  23. 23. He H, Pham-Huy LA, Dramou P, Xiao D, Zuo P, et al. (2013) Carbon nanotubes: applications in pharmacy and medicine. BioMed research international 2013: 578290.
  24. 24. Bhattacharya S, Alkharfy KM, Janardhanan R, Mukhopadhyay D (2012) Nanomedicine: pharmacological perspectives. Nanotechnol Rev 1: 235–253.
  25. 25. Song G, Ouyang G, Mao Y, Ming Y, Bao S, et al. (2009) Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. Journal of cellular and molecular medicine 13: 1706–1718.
  26. 26. Liu F, Yang X, Ding B, Ren G, Gong R (2009) The expression of HIF-1α and VEGF as well as their correlation with angiogenesis in esophageal squamous cell carcinomas. The Chinese-German Journal of Clinical Oncology 8: 199–202.
  27. 27. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer treatment reviews 29: 297–307.
  28. 28. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, et al. (2007) Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Molecular pharmacology 72: 162–172.
  29. 29. Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer metastasis reviews 26: 225–239.
  30. 30. Naruse T, Kawasaki G, Yanamoto S, Mizuno A, Umeda M (2011) Immunohistochemical study of VEGF expression in oral squamous cell carcinomas: correlation with the mTOR-HIF-1alpha pathway. Anticancer research 31: 4429–4437.
  31. 31. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, et al. (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22: 3213–3220.
  32. 32. Zhou Y, Tozzi F, Chen J, Fan F, Xia L, et al. (2012) Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer research 72: 304–314.
  33. 33. Doe MR, Ascano JM, Kaur M, Cole MD (2012) Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer research 72: 949–957.
  34. 34. Huang L, Ao Q, Zhang Q, Yang X, Xing H, et al. (2010) Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. Journal of cancer research and clinical oncology 136: 447–456.
  35. 35. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, et al. (1995) Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer research 55: 3564–3568.
  36. 36. Milas L, Hunter N, Mason KA, Milross C, Peters LJ (1995) Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta oncologica 34: 409–412.
  37. 37. Flamant L, Notte A, Ninane N, Raes M, Michiels C (2010) Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Molecular cancer 9: 191.
  38. 38. Zhang R, Zhu F, Ren J, Huang L, Liu P, et al. (2011) Beclin1/PI3K-mediated autophagy prevents hypoxia-induced apoptosis in EAhy926 cell line. Cancer biotherapy & radiopharmaceuticals 26: 335–343.
  39. 39. Shi Y, Chang M, Wang F, Ouyang X, Jia Y, et al. (2010) Role and mechanism of hypoxia-inducible factor-1 in cell growth and apoptosis of breast cancer cell line MDA-MB-231. Oncology letters 1: 657–662.
  40. 40. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, et al. (2006) Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. The Journal of biological chemistry 281: 25903–25914.
  41. 41. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, et al. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer research 59: 5830–5835.
  42. 42. Yang ST, Luo J, Zhou Q, Wang H (2012) Pharmacokinetics, metabolism and toxicity of carbon nanotubes for biomedical purposes. Theranostics 2: 271–282.